Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease

Background Pathogenic variants in the LRRK2 gene are a common monogenic cause of Parkinson’s disease. However, only seven variants have been confirmed to be pathogenic. Objectives We identified two novel LRRK2 variants (H230R and A1440P) and performed functional testing. Methods We transiently expressed wildtype, the two new variants, or two known pathogenic mutants (G2019S and R1441G), in HEK-293T cells, with or without LRRK2 kinase inhibitor treatment. We characterized the phosphorylation and kinase activity of the mutants by western blotting. Thermal shift assays were performed to determine the folding and stability of the LRRK2 proteins. Results The two variants were found in two large families and segregate with the disease. They display altered LRRK2 phosphorylation and kinase activity. Conclusions We identified two novel LRRK2 variants which segregate with the disease. The results of functional testing lead us to propose these two variants as novel causative mutations for familial Parkinson’s disease.

[1]  Huidong Tang,et al.  A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease , 2022, Movement disorders : official journal of the Movement Disorder Society.

[2]  X. Thuru,et al.  A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively , 2022, Cells.

[3]  M. Bolliger,et al.  Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation , 2021, Neurobiology of Disease.

[4]  A. Myasnikov,et al.  Structural analysis of the full-length human LRRK2 , 2021, Cell.

[5]  M. Chartier-Harlin,et al.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells , 2021, Cells.

[6]  E. Tolosa,et al.  R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils , 2021, Acta Neuropathologica.

[7]  E. Tan,et al.  Identification of Targets from LRRK2 Rescue Phenotypes , 2021, Cells.

[8]  T. Iwatsubo,et al.  The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System , 2020, Frontiers in Neuroscience.

[9]  D. Alessi,et al.  Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease , 2020, Current opinion in cell biology.

[10]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[11]  B. Baker,et al.  LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain , 2019, Small GTPases.

[12]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[13]  A. Kishore,et al.  Understanding the role of genetic variability in LRRK2 in Indian population , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  M. Cookson,et al.  LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network , 2018, Human molecular genetics.

[15]  S. Pfeffer,et al.  Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase , 2017, The EMBO journal.

[16]  L. Bubacco,et al.  GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2 , 2017, Human molecular genetics.

[17]  G. Hadjigeorgiou,et al.  Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations , 2016, PloS one.

[18]  G. Jarvik,et al.  Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. , 2016, American journal of human genetics.

[19]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[20]  S. Cragg,et al.  LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function , 2016, Human molecular genetics.

[21]  Lynn A. Hyde,et al.  MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[22]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[23]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[24]  R. Nichols,et al.  LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status , 2014, Front. Mol. Neurosci..

[25]  M. Farrer,et al.  Advances in the genetics of Parkinson disease , 2013, Nature Reviews Neurology.

[26]  K. Scearce-Levie,et al.  Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations , 2012, Science Translational Medicine.

[27]  A. Grünewald,et al.  Genetics of Parkinson's Disease , 2011, Seminars in neurology.

[28]  A. Prescott,et al.  14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.

[29]  J. Jankovic,et al.  Multiple LRRK2 variants modulate risk of Parkinson disease: a chinese multicenter study , 2010, Human mutation.

[30]  M. Goldberg,et al.  Regulation of LRRK2 Stability by the E3 Ubiquitin Ligase CHIP , 2009, PloS one.

[31]  W. Dauer,et al.  The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration , 2009, The Journal of Neuroscience.

[32]  J. Johnson,et al.  Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants , 2007, European journal of neurology.

[33]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[34]  Christine Klein,et al.  Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.